Senzime AB (publ) (SEZI.ST)
SEK 5.68
(24.15%)
SEK 5.68
(24.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -139.54 Million SEK | -974.05% |
| 2022 | -12.99 Million SEK | 82.26% |
| 2021 | -73.23 Million SEK | 53.62% |
| 2020 | -157.91 Million SEK | -417.58% |
| 2019 | -30.51 Million SEK | 5.81% |
| 2018 | -32.39 Million SEK | -270.71% |
| 2017 | -8.73 Million SEK | 12.86% |
| 2016 | -10.02 Million SEK | 30.57% |
| 2015 | -14.44 Million SEK | -378.05% |
| 2014 | -3.02 Million SEK | 69.56% |
| 2013 | -9.92 Million SEK | -82.51% |
| 2012 | -5.43 Million SEK | -20.07% |
| 2011 | -4.52 Million SEK | -748.61% |
| 2010 | 698.16 Thousand SEK | -77.73% |
| 2009 | 3.13 Million SEK | 350.4% |
| 2008 | -1.25 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -105.63 Million SEK | 24.3% |
| 2024 Q2 | -56.11 Million SEK | 46.88% |
| 2023 FY | -139.54 Million SEK | -974.05% |
| 2023 Q4 | -139.54 Million SEK | -140.89% |
| 2023 Q1 | -61.56 Million SEK | -373.85% |
| 2023 Q2 | -29.16 Million SEK | 52.63% |
| 2023 Q3 | -57.92 Million SEK | -98.65% |
| 2022 Q3 | -43.72 Million SEK | 64.89% |
| 2022 Q4 | -12.99 Million SEK | 70.28% |
| 2022 Q1 | -54.96 Million SEK | 24.96% |
| 2022 FY | -12.99 Million SEK | 82.26% |
| 2022 Q2 | -124.52 Million SEK | -126.56% |
| 2021 FY | -73.23 Million SEK | 53.62% |
| 2021 Q2 | -116.8 Million SEK | 17.11% |
| 2021 Q1 | -140.91 Million SEK | 10.76% |
| 2021 Q3 | -95.71 Million SEK | 18.05% |
| 2021 Q4 | -73.23 Million SEK | 23.48% |
| 2020 Q2 | -83.97 Million SEK | -249.95% |
| 2020 Q1 | -23.99 Million SEK | 21.35% |
| 2020 FY | -157.91 Million SEK | -417.58% |
| 2020 Q4 | -157.91 Million SEK | -116.51% |
| 2020 Q3 | -72.93 Million SEK | 13.14% |
| 2019 Q4 | -30.51 Million SEK | 21.62% |
| 2019 FY | -30.51 Million SEK | 5.81% |
| 2019 Q2 | -14.83 Million SEK | 28.55% |
| 2019 Q1 | -20.75 Million SEK | 34.89% |
| 2019 Q3 | -38.92 Million SEK | -162.49% |
| 2018 Q3 | -13.04 Million SEK | 35.56% |
| 2018 Q2 | -20.24 Million SEK | 25.86% |
| 2018 FY | -32.39 Million SEK | -270.71% |
| 2018 Q4 | -31.87 Million SEK | -144.32% |
| 2018 Q1 | -27.31 Million SEK | -265.84% |
| 2017 Q1 | -3.78 Million SEK | 62.28% |
| 2017 Q2 | -19.48 Million SEK | -415.12% |
| 2017 Q3 | -14.82 Million SEK | 23.92% |
| 2017 Q4 | -7.46 Million SEK | 49.63% |
| 2017 FY | -8.73 Million SEK | 12.86% |
| 2016 Q4 | -10.02 Million SEK | 36.41% |
| 2016 Q3 | -15.76 Million SEK | -97.8% |
| 2016 FY | -10.02 Million SEK | 30.57% |
| 2016 Q2 | -7.97 Million SEK | 33.24% |
| 2016 Q1 | -11.93 Million SEK | 17.33% |
| 2015 FY | -14.44 Million SEK | -378.05% |
| 2015 Q3 | -17.3 Million SEK | 10.86% |
| 2015 Q4 | -14.44 Million SEK | 16.56% |
| 2015 Q1 | -12.56 Million SEK | -316.06% |
| 2015 Q2 | -19.41 Million SEK | -54.47% |
| 2014 FY | -3.02 Million SEK | 69.56% |
| 2014 Q4 | -3.02 Million SEK | 47.21% |
| 2014 Q3 | -5.72 Million SEK | 18.99% |
| 2014 Q2 | -7.06 Million SEK | -169.89% |
| 2014 Q1 | 10.1 Million SEK | 201.86% |
| 2013 Q4 | -9.92 Million SEK | 0.0% |
| 2013 Q2 | -1.7 Million SEK | 0.0% |
| 2013 Q1 | -1.7 Million SEK | 68.62% |
| 2013 FY | -9.92 Million SEK | -82.51% |
| 2012 Q4 | -5.43 Million SEK | 0.0% |
| 2012 FY | -5.43 Million SEK | -20.07% |
| 2012 Q2 | -2.21 Million SEK | 0.0% |
| 2011 FY | -4.52 Million SEK | -748.61% |
| 2011 Q4 | -4.52 Million SEK | 0.0% |
| 2011 Q2 | -4.6 Million SEK | 0.0% |
| 2010 Q4 | 698.16 Thousand SEK | 0.0% |
| 2010 Q2 | -386.39 Thousand SEK | 0.0% |
| 2010 FY | 698.16 Thousand SEK | -77.73% |
| 2009 Q4 | 3.13 Million SEK | 0.0% |
| 2009 FY | 3.13 Million SEK | 350.4% |
| 2008 FY | -1.25 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | -296.998% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 111.373% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 111.373% |
| Arcoma AB | -1.12 Million SEK | -12270.656% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 226.992% |
| BICO Group AB (publ) | 927.9 Million SEK | 115.038% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 208.339% |
| CellaVision AB (publ) | -56.94 Million SEK | -145.058% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -837.965% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -1550.355% |
| C-Rad AB (publ) | -127.6 Million SEK | -9.358% |
| Duearity AB (publ) | 10.23 Million SEK | 1463.904% |
| Dignitana AB (publ) | 13.07 Million SEK | 1167.072% |
| Episurf Medical AB (publ) | -52.7 Million SEK | -164.784% |
| Getinge AB (publ) | 5.4 Billion SEK | 102.58% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | -298.085% |
| Iconovo AB (publ) | -10.75 Million SEK | -1197.412% |
| Integrum AB (publ) | -10.47 Million SEK | -1231.938% |
| Luxbright AB (publ) | -13.83 Million SEK | -908.72% |
| Mentice AB (publ) | -49.56 Million SEK | -181.537% |
| OssDsign AB (publ) | -162.78 Million SEK | 14.281% |
| Paxman AB (publ) | -11.41 Million SEK | -1122.864% |
| Promimic AB (publ) | -50.32 Million SEK | -177.291% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 831.73% |
| SciBase Holding AB (publ) | -27.32 Million SEK | -410.69% |
| ScandiDos AB (publ) | -1.53 Million SEK | -9014.37% |
| Sectra AB (publ) | -772.85 Million SEK | 81.945% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 38.494% |
| SpectraCure AB (publ) | -50.23 Million SEK | -177.782% |
| Stille AB | -178.5 Million SEK | 21.828% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 111.363% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 34.992% |